Sharing the Decision Slide Set:
Bibliography

Adolfsson J, Helgason AR, Dickman P, Steineck G. Urinary and bowel symptoms in men with and without prostate cancer: results from an observational study in the Stockholm area. European Urology 1998;33(1):11–16. (slide 30)

Albertsen PC, Hanley JA, Gleason DF, Barry MJ. Competing risk analysis of men aged 55 to 74 years at diagnosis managed conservatively for clinically localized prostate cancer. JAMA 1998;280(11):975–980. (slides 11, 19, 27, 28, 29)

Albertsen PC. The prostate cancer conundrum. 2003;95:930-931.

Albertsen PC, Walters S, Hanley JA. A comparison of cause of death determination in men previously diagnosed with prostate cancer who died in 1985 or 1995. Journal of Urology 2000;163(2):519–523. (slide 21)

American Academy of Family Physicians. AAFP Summary of Policy Recommendations for Periodic Health Examination. (Revision 5.1). Leawood, KS: American Academy of Family Physicians; 2001. (slide 2)

American College of Physicians, American Society of Internal Medicine. Screening for prostate cancer. Annals of Internal Medicine 1997;126(7):480–484. (slide 2)

American Diabetes Association, National Institute of Diabetes and Digestive and Kidney Diseases. The prevention or delay of type 2 diabetes. Diabetes Care 2003;26(suppl 1):S61–S69. (slide 37)

American Medical Association. Featured CSA Report: Screening and Early Detection of Prostate Cancer. Chicago IL: Council on Scientific Affairs; 2000. (slide 2)

American Urological Association. Prostate Cancer Awareness for Men. Baltimore, MD: American Urological Association; 2000. (slide 41)

American Urological Association. Prostate specific antigen (PSA): best practice policy. Oncology 2000;14:267–272, 277–278, 280 passim. (slide 2)

Amin H, Grignot D, Humphrey PA, et al. Gleason grading of prostate cancer: a contemporary approach. Lippincott. 2003; In Press. (slide 29)

Barry MJ. Involving patients in medical decisions: how can physicians do better? JAMA 1999;282(24):2356–2357. (slides 35, 36)

Barry MJ. Health decision aids to facilitate shared decision making on office practice. Annals of Internal Medicine 2002;136(2):127–135. (slides 32, 35, 36)

Bartsch G, Horninger W, Klocker H, et al. Decrease in prostate cancer mortality following introduction of prostate specific antigen (PSA) screening in the federal state of Tyrol, Austria. Journal of Urology 2000;163(suppl):88. (slide 21)

Bartsch G, Horninger W, Klocker H, Reissigl A, Oberaigner W, Schonitzer D, Robertson C, Boyle P. Prostate cancer mortality after introduction of prostate-specific antigen mass screening in the federal state of Tyrol, Austria. Urology 2001;58:417–424. (slide 21)

Beard CJ, Propert KJ, Reiker PP, Clark JA, Kaplan I, Kantoff PW, Talcott JA. Complications after treatment with external-beam irradiation in early-stage prostate cancer patients: a prospective multiinstitutional outcomes study. Journal of Clinical Oncology 1997;15(1):223–229. (slide 30)

Brandeis JM, Litwin MS, Burnison CM, Reiter RE. Quality of life outcomes after brachytherapy for early stage prostate cancer. Journal of Urology 2000;163(3):851–857. (slide 30)

Brawley OW. Prostate carcinoma incidence and patient mortality: the effects of screening and early detection. Cancer 1997(9);80:1857–1863. (slide 21)

Briss P, Rimer B, Reilley B, Coates RJ, Lee NC, Mullen P, Corso P, Hutchinson AB, Hiatt R, Kerner J, George P,White C, Gandhi N, Saraiya M, Breslow R, Isham G, Teutsch SM, Hinman AR, Lawrence R. Promoting informed decisions about cancer screening in communities and healthcare systems. American Journal of Preventive Medicine 2004;26:67-80.

Catalona WJ, Richie JP, Ahmann FR, Hudson MA, Scardino PT, Flanigan RC, deKernion JB, Ratliff TL, Kavoussi LR, Dalkin BL, et al. Comparison of digital rectal examination and serum prostate specific antigen in the early detection of prostate cancer: results of a multicenter clinical trial of 6,630 men. Journal of Urology 1994;151(5):1283–1290. (slides 17, 25)

Centers for Disease Control and Prevention. Prostate Cancer: Can We Reduce Deaths and Preserve Quality of Life? At-a-Glance 1999. Atlanta, GA: Centers for Disease Control and Prevention; 1999. (slide 41)

Chaikin DC, Broderick GA, Malloy TR, Malkowicz SB, Wittington R, Wein AJ. Erectile dysfunction following minimally invasive treatments for prostate cancer. Urology1996;48(1):100–104. (slide 30)

Chan EC. Promoting informed decision making about prostate cancer screening. Comprehensive Therapy 2001;27(3):195–201. (slides 35, 36, 39, 40, 41, 42, 43)

Chan EC, Sulmasy DP. What should men know about prostate-specific antigen screening before giving informed consent? American Journal of Medicine 1998;105(4):266–274. (slide 38)

Chodak GW, Thisted RA, Gerber GS, Johansson JE, Adolfsson J, Jones GW, Chisholm GD, Moskoviz B, Livne PM, Warner J. Results of conservative management of clinically localized prostate cancer. New England Journal of Medicine 1994;330(4):242–248. (slides 11, 19, 27, 28, 29)

Daniell HW, Dunn SR, Ferguson DW, Lomas G, Niazi Z, Stratte PT. Progressive osteoporosis during androgen deprivation therapy for prostate cancer. Journal of Urology 2000;163(1):181–186. (slide 30)

Davison BJ, Kirk P, Degner LF, Hassard TH. Information and participation in screening for prostate cancer. Patient Education and Counseling 1999;37(3):255–263. (slides 39, 40, 41, 42, 43)

Dearnaley DP, Khoo VS, Norman AR, Meyer L, Nahum A, Tait D, Yarnold J, Horwich A. Comparison of radiation side-effects of conformal and conventional radiotherapy in prostate cancer: a randomised trial. Lancet 1999;353(9149)267–272. (slide 30)

Draisma G, Boer R, Otto SJ, van der Cruijsen, Damhuis RA, Schroder FH, de Koning HJ. Lead times and overdetection due to prostate-specific antigen screening: estimates from the European Randomized Study of Screening for Prostate Cancer. Journal of the National Cancer Institute 2003;95(12):868-878.

Edwards A, Elwyn G. The potential benefits of decision aids in clinical medicine. JAMA 1999;282(8):779–780. (slides 35, 36)

Epstein JI. Gleason score 2–4 adenocarcinoma of the prostate on needle biopsy: a diagnosis that should not be made. American Journal of Surgical Pathology. 2000;24(4):477–478. (slides 11, 27, 29)

Etzioni R, Legler JM, Feuer EJ, Merrill RM, Cronin KA, Hankey BF. Cancer surveillance series: interpreting trends in prostate cancer—part III: quantifying the link between population prostate-specific antigen testing and recent declines in prostate cancer mortality. Journal of the National Cancer Institute 1999;91(12):1033–1039. (slide 21)

Etzioni R, Penson DF, Legler JM, di Tommaso D, Boer R, Gann PH, Feuer EJ. Overdiagnosis due to prostate-specific antigen screening: lessons from U.S. prostate incidence trends. Journal of the National Cancer Institute 2002;94(13):981–990. (slides 7, 11, 17, 26, 27, 28, 29)

Farrell MH, Murphy MA, Schneider CE. How underlying patient beliefs can affect physician-patient communication about prostate cancer antigen testing. Effective Clinical Practice 2002;5(3):120–129. (slide 43)

Feldman-Stewart D, Brundage MD, McConnell BA, MacKillop WJ. Practical issues in assisting shared decision-making. Health Expectations 2000;3 (1):46–54. (slide 35, 36)

Ferrini R, Woolf SH. Screening for prostate cancer in American men. American Journal of Preventive Medicine 1998:15(1):81–84. (slide 2).

Feuer EJ, Merrill RM, Hankey BF. Cancer surveillance series: interpreting trends in prostate cancer—part II: cause of death misclassification and the recent rise and fall in prostate cancer mortality. Journal of the National Cancer Institute 1999;91(12):1025–1032. (slide 21)

Feuer EJ, Wun LM. DEVCAN: Probability of Developing or Dying of Cancer Software, Version 4.1. Bethesda, MD: National Cancer Institute; 1999. (slides 5, 6, 8, 9)

Flood AB, Wennberg JE, Nease RF Jr, Fowler FJ Jr, Ding J, Hynes LM. The importance of patient preference in the decision to screen for prostate cancer. Prostate Patient Outcomes Research Team. Journal of General Internal Medicine 1996;11:342–349. (slides 39, 40, 41, 42, 43)

Fossa SD, Woehre H, Hurth KH, Hetherington J, Bakke H, Rustad DA, Skanvik R. Influence of urological morbidity on quality of life in patients with prostate cancer. European Urology 1997;31(suppl 3):3–8. (slide 30)

Fowler FJ Jr, Barry MJ, Lu-Yao G, Wasson JH, Bin L. Outcomes of external-beam radiation therapy for prostate cancer: a study of Medicare beneficiaries in three surveillance, epidemiology, and end result areas. Journal of Clinical Oncology 1996;14(8):2258–2265. (slide 30)

Fransson P, Widmark A. Self-assessed sexual function after pelvic irradiation for prostate carcinoma. Comparison with an age-matched control group. Cancer 1996;78(5):1066–1078. (slide 30)

Frosch DL, Kaplan RM. Shared decision making in clinical medicine: past research and future directions. American Journal of Preventive Medicine 1999;17(4):285–294. (slides 35, 36, 38)

Frosch DL, Kaplan RM, Felitti V. Evaluation of two methods to facilitate shared decision making for men considering the prostate-specific antigen test. Journal of General Internal Medicine 2001;16(6):391–398. (slides 39, 40, 41, 42, 43)

Fulmer BR, Bissonette EA, Petroni GR, Theodorescu D. Prospective assessment of voiding and sexual function after treatment for localized prostate carcinoma: comparison of radical prostatectomy to hormonobrachytherapy with and without external beam radiotherapy. Cancer 2001;91(11):2046–2055. (slide 30)

Gann P, Hennekens C, Stampfer M. A prospective evaluation of plasma prostate-specific antigen for detection of prostatic cancer. JAMA 1995;273(4):289–294. (slides 17, 21)

Gerber GS, Thisted RA, Scardino PT, Frohmuller HG, Schroeder FH, Paulson DF, Middleton AW Jr, Rukstalis DB, Smith JA Jr, Schellhammer PF, Ohori M, Chodak GW. Results of radical prostatectomy in men with clinically localized prostate cancer. JAMA 1996;276(8):615–619. (slide 19)

Gilliland FD, Gleason DF, Hunt WC, Stone N, Harlan LC, Key CR. Trends in Gleason score for prostate cancer diagnosed between 1983 and 1993. Journal of Urology 2001;165(3):846–850. (slides 26, 29)

Hamilton AS, Stanford JL, Gilliland FD, Albertsen PC, Stephenson RA, Hoffman RM, Eley JW, Harlan LC, Potosky AL. Health outcomes after external-beam radiation therapy for clinically localized prostate cancer: results from the Prostate Cancer Outcomes Study. Journal of Clinical Oncology 2001;19(9):2517–2526. (slide 30)

Hankey BF, Feuer EJ, Clegg LX, Hayes RB, Legler JM, Prorok PC, Ries LA, Merrill RM, Kaplan RS. Cancer surveillance series: interpreting trends in prostate cancer—part I. Evidence of the effects of screening in recent prostate cancer incidence, mortality, and survival rates. Journal of the National Cancer Institute 1999;91(12):1017–1024. (slide 21)

Hanks GE. The case for external beam treatment of early-stage prostate cancer. Urology 2000;55(3):301–305. (slide 19)

Harris R, Lohr KN. Screening for prostate cancer: an update of the evidence for the U.S. Preventive Task Force. Annals of Internal Medicine 2002;137(11):917–929. (slides 2, 10, 17, 19, 30, 35)

Helgason AR, Adolfsson J, Dickman P, Arver S, Fredrikson M, Steineck G. Factors associated with waning sexual function among elderly men and prostate cancer patients. Journal of Urology 1997;158(1):155–159. (slide 30)

Helgason AR, Adolfsson J, Dickman P, Fredrikson M, Arver S, Steineck G. Waning sexual function—the most important disease-specific distress for patients with prostate cancer. British Journal of Cancer 1996;73(11):1417–1421. (slide 30)

Hoedemaeker RF, Rietbergen JB, Kranse R, Kwast TH, Schroder FH. Comparison of pathologic characteristics of T1c and non-T1c cancers detected in a population-based screening study: the European randomized study of screening for prostate cancer. World Journal of Urology 1997;15(6):339–345. (slide 17)

Holmberg L, Axelson AB, Helgensen F, Salo JO, Folmerz P. A randomized trial comparing radical prostatectomy with watchful waiting in early prostate cancer. New England Journal of Medicine 2002;347(11):781–789. (slide 20)

Holmes-Rovner M, Valade D, Orlowski C, Draus C, Nabozny-Valero B, Keiser S. Implementing shared decision-making in routine practice: barriers and opportunities. Health Expectations 2000;3(3):182–191. (slide 38)

Horninger W, Reissigl A, Klocker H, et al. Improvement of specificity in PSA-based screening by using PSA-transition zone density and percent free PSA in addition to total PSA levels. Prostate 1998;37:133–137, discussion 138–139. (slide 17)

Horninger W, Reissigl A, Rogatsch H, et al. Prostate cancer screening in the Tyrol, Austria: experience and results. European Journal of Cancer 2000;36(10):1322–1335. (slide 25)

Hsing A, Nomurs AM, Isaacs WB, Armenian HK. Prostate cancer. Epidemiological Review 2001;23:1–190. (slide 12)

Humphrey PA, Keetch DW, Smith DS, Shepherd DL, Catalona WJ. Prospective characterization of pathological features of prostatic carcinomas detected via serum prostate specific antigen based screening. Journal of Urology 1996;155(3):816-820. (slides 10, 11, 26, 27, 28, 29)

Johansson JE, Holmberg L, Johansson S, Bergstrom R, Adami HO. Fifteen-year survival in prostate cancer: a prospective, population-based study in Sweden. JAMA 1997;277(3):467–471. (slides 11, 19, 27, 28, 29)

Kaplan RM. Shared medical decision-making: new paradigm for behavioral medicine—1997 presidential address. Annals of Behavioral Medicine 1999;21:3–11. (slide 38)

Knowler WC, Barrett-Connor E, Fowler SE, et al. Diabetes prevention program research group. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. New England Journal of Medicine 2002;6:393–403. (slide 37)

Krongrad A, Lai H, Lai S. Survival after radical prostatectomy. JAMA 1997;278(1):44–46. (slide 19)

Krupski T, Petroni GR, Bissonette EA, Theodorescu D. Quality-of-life comparison of radical prostatectomy and intestinal brachytherapy in the treatment of clinically localized prostate cancer. Urology 2000;55(5):736–742. (slide 30)

Labrie F, Candas B, Cusan L, Gomez JL, Diamond P, Suburu R, Lemay M. Diagnosis of advanced or noncurable prostate cancer can be practically eliminated by prostate-specific antigen. Urology 1996;47(2):212–217. (slides 17, 25)

Labrie F, Candas B, Dupont A, Cusan L, Gomez JL, Suburu RE, Diamond R, Levesque J, Belanger A. Screening decreases prostate cancer death: first analysis of the 1988 Quebec prospective randomized control trial. Prostate 1999;38(2):83–91. (slide 25)

Labrie F, DuPont A, Suburu R, Cusan L, Tremblay M, Gomez JL, Emond J. Serum prostate specific antigen as pre-screening test for prostate cancer. Journal of Urology 1992;147(3 Pt 2):846–852. (slides 17, 25)

Labrie F, Dupont A, Suburu R, Cusan L, Gomez JL, Koutsilieris M, Diamond P, Emond J, Lemay M, Candas B. Optimized strategy for detection of early stage curable prostate cancer: role of prescreening with prostate-specific antigen. Clinical and Investigative Medicine 1993;16(6):425–439. (slides 17, 25)

Lee WR, McQuellon RP, Case LD, deGuzman AF, McCullough DL. Early quality of life assessment in men treated with permanent source interstitial brachytherapy for clinically localized prostate cancer. Journal of Urology 1999;162(2):403–406. (slide 30)

Lee WR, McQuellon RP, Harris-Henderson K, Case LD, McCullough DL. A preliminary analysis of health-related quality of life in the first year after permanent source interstitial brachytherapy (PIB) for clinically localized prostate cancer. International Journal of Radiation, Oncology, Biology, Physics 2000;46(1):77–81. (slide 30)

Levi F, La Vecchia C, Boyle P. The rise and fall of prostate cancer. European Journal of Cancer Prevention 2000;9(6):381–385. (slide 21)

Liao L, Jollis JG, Delong ER, Peterson ED, Morris KG, Mark DB. Impact of interactive video on decision making of patients with ischemic heart disease. Journal of General Internal Medicine 1996;11(6):373–376. (slide 37)

Litwin MS. Health-related quality of life after treatment for localized prostate cancer. Cancer 1995;75:2000–2003. (slide 30)

Litwin MS. Editorial comments. Journal of Urology 2000;163:1806–1807. (slide 30)

Litwin MS, Flanders SC, Pasta DJ, Stoddard ML, Lubeck DP, Henning JM. Sexual function and bother after radical prostatectomy or radiation for prostate cancer: multivariate quality-of-life analysis from CaPSURE. Cancer of the Prostate Strategic Urologic Research Endeavor. Urology 1999;54(3):503–508. (slide 30)

Litwin MS, Hays RD, Fink A, Ganz PA, Leake B, Leach GE, Brook RH. Quality-of-life outcomes in men treated for localized prostate cancer. JAMA 1995;273:129–135. (slide 30)

Litwin MS, Melmed GY, Nakazon T. Life after radical prostatectomy: a longitudinal study. Journal Urology 2001;166(2):587–592. (slide 30)

Lu-Yao G, Albertsen PC, Stanford JL, Stukel TA, Walker-Corkery ES, Barry MJ. Natural experiment examining impact of aggressive screening and treatment on prostate cancer mortality in two fixed cohorts from Seattle area and Connecticut. British Medical Journal 2002;325(7367):725–726. (slides 21, 22)

Lu-Yao GL, Yao SL. Population-based study of long-term survival in patients with clinically localized prostate cancer. Lancet 1997;349(9056):906–910. (slides 11, 27, 28, 29)

Maatanen L, Auvinen A, Stenman UH, Rannikko S, Tammela T, Aro J, Juusela H, Hakama M. European randomized study of prostate cancer screening: first-year results of the Finnish trial. British Journal of Cancer 1999;79(7-8):1210–1214. (slide 25)

Madalinski JB, Essink-Bot ML, de Koning HJ, Kirkels WJ, van der Maas PJ, Schroder FH. Health-related quality-of-life effects of radical prostatectomy and primary radiotherapy for screen-detected or clinically diagnosed localized prostate cancer. Journal of Clinical Oncology 2001;19(6):1619–1628. (slide 30)

Martin E, Lujan M, Sanchez E, Herrero A, Paez A, Berenguer A. Final results of a screening campaign for prostate cancer. European Urology 1999;35(1):26–31. (slides 17, 25)

Meyer F, Moore L, Bairati I, Fadet Y. Downward trend in prostate cancer mortality in Quebec and Canada. Journal of Urology 1999;161:529–533. (slide 21)

Morgan MW, Deber RB, Llewellyn-Thomas HA, et al. Randomized, controlled trial of an interactive videodisc decision aid for patients with ischemic heart disease. Journal of General Internal Medicine 2000;15(10):685–693. (slide 37)

Murphy GP, Natarajan N, Pontes JE, Schmitz RL, Smart CR, Schmidt JD, Mettlin C. The national survey of prostate cancer in the United States by the American College of Surgeons.Journal of Urology 1982;127(5):928–934. (slide 17)

National Cancer Institute. SEER incidence data 1995-1999. Rockville, MD; 2002. (slides 5, 6, 8, 9)

National Cancer Institute. What You Need To Know About Prostate Cancer. Bethesda, MD: National Institutes of Health; 2000. US Dept of Health and Human Services, NIH publication 00–1576. (slide 43)

National Center for Health Statistics. National Vital Statistics Report. (slides 5, 6, 8, 9)

Newcomer LM, Stanford JL, Blumenstein BA, Brawer MK. Temporal trends in rates of prostate cancer: declining incidence of advanced stage disease, 1974 to 1994. Journal of Urology 1997;158(4):1427–1430. (slide 17)

Nguyen LN, Pollack A, Zagars GK. Late effects after radiotherapy for prostate cancer in a randomized dose-response study: results of a self-assessment questionnaire. Urology 1998;51(6):991–997. (slide 30)

O’Connor AM, Rostom A, Fiset V, Tetroe J, Entwistle V, Llewellyn-Thomas H, Holmes-Rovner M, Barry M, Jones J. Decision aids for patients facing health treatment or screening decisions: systematic review. British Medical Journal 1999;319(7212):731–734. (slides 35, 36)

O’Connor AM, Stacey D, Rovner D, et al. Decision aids for people facing health treatment or screening decisions. Cochrane Database Syst Rev. 2001;3:CD001431. (slides 35, 36)

O’Dell KJ, Volk RJ, Cass AR, Spann SJ. Screening for prostate cancer with the prostate-specific antigen test: are patients making informed decisions? Journal of Family Practice 1999;48(9):682–688. (slides 35, 36, 39, 40, 41, 42, 43)

Office of Technology Assessment. Costs and Effectiveness of Prostate Cancer Screening in Elderly Men. Washington, DC: US Government Printing Office; 1995:19, table 2-5. Publication OTA-BP-H-145. (slide 10)

Oliver SE, Gunnell D, Donovan JL. Comparison of trends in prostate-cancer mortality in England and Wales and the USA. Lancet 2000;355(9217):1788–1789. (slides 21, 22)

Paulson D. Impact of radical prostatectomy in the management of clinically localized disease. Journal of Urology 1994;152(5 Pt 2):1826–1830. (slide 19)

Potosky AL, Feuer EJ, Levin DL. Impact of screening on incidence and mortality of prostate cancer in the United States. Epidemiological Review 2001;23(1):181–186. (slide 21)

Potosky AL, Knopf K, Clegg LX, et al. Quality-of-life outcomes after primary androgen deprivation therapy: results from the Prostate Outcomes Study. Journal of Clinical Oncology 2001;19:3750–3757. (slides 30)

Potosky AL, Legler J, Albertsen PC, Stanford JL, Gilliland FD, Hamilton AS, Eley JW, Stephenson RA, Harlan LC. Health outcomes after prostatectomy or radiotherapy for prostate cancer: results from the Prostate Cancer Outcomes Study. Journal of the National Cancer Institute 2000;92(19):1582–1592. (slide 30)

Potosky AL, Miller BA, Albertsen PC, Kramer BS. The role of increasing detection in the rising incidence of prostate cancer. JAMA 1995;273(7):548–552. (slide 7)

Potosky AL, Reeve BB, Clegg LX, Hoffman RM, Stephenson RA, Albertsen PC, Gilliland FD, Stanford JL. Quality of life following localized prostate cancer initially treated with androgen deprivation therapy or no therapy. Journal of the National Cancer Institute 2002;94(6):430–437. (slide 30)

Richie JP, Catalona WJ, Ahmann FR, Hudson MA, Scardino PT, Flanigan RC, deKernion JB, Ratliff TL, Kavoussi BR, Dalkin BL, et al. Effect of patient age on early detection of prostate cancer with serum prostate specific antigen and digital rectal examination. Urology 1993;42(4):365–374. (slides 17, 25)

Ries LAG, Eisner MP, Kosary CL, et al., eds. SEER Cancer Statistics Review, 1973–1999. Bethesda, MD: National Cancer Institute; 2002. (slides 7, 8, 9, 21)

Roach M III, Chinn DM, Holland J, Clark M. A pilot survey of sexual function and quality of life following 3D conformal radiotherapy for clinically localized prostate cancer. International Journal of Radiation, Oncology, Biology, Physics 1996;35:869–874. (slide 30)

Roach M III, Lu J, Pilepich MV, Asbell SO, Mohiuddin M, Terry R, Grignon D. Long-term survival after radiotherapy alone: prostate cancer trials. Journal of Urology 1999;161(3):864–868. (slide 19)

Roach M, Lu J, Pilepich MV, Asbell SO, Mohiuddin M, Terry R, Grignon D, Mohuidden M. Four prognostic groups predict long-term survival from prostate cancer following radiotherapy alone on Radiation Therapy Oncology Group clinical trials. International Journal of Radiation, Oncology, Biology, Physics 2000;47(3):609–615. [Erratum, International Journal of Radiation, Oncology, Biology, Physics 2000;48(1):313.] (slide 19)

Robert AS, von Eschenbach AC, Wender R, Levin B, Byers T, Rothenberger D, Brooks D, Creasman W, Cohen C, Runowicz C, Saslow D, Cokkinides, Eyre H.. American Cancer Society guidelines for the early detection of cancer: update of early detection guidelines for prostate, colorectal, and endometrial cancer. CA: A Cancer Journal for Clinicians 2001;51:38–75. (slide 2)

Roberts RO, Bergstralh EJ, Katusic SK, Lieber MM, Jacobsen SJ. Decline in prostate cancer mortality from 1980 to 1997, and an update on incidence trends in Olmsted County, Minnesota. Journal of Urology 1999;161(2):529–533. (slide 21)

Robinson JW, Dufour MS, Fung TS. Erectile functioning of men treated for prostate carcinoma. Cancer 1997;79(3):538–544. (slide 30)

Schapira MM, Vanruiswyk J. The effect of an illustrated pamphlet decision-aid on the use of prostate cancer screening tests. Journal of Family Practice 2000;49(5):418–424. (slides 39, 40, 41, 42, 43)

Schmid HP, McNeal JE, Stamey TA. Observations on the doubling time of prostate cancer. Cancer 1993;71(6):2031–2040. (slide 21)

Schroder FH, van der Cruijsen-Koeter I, de Koning HJ, Vis AN, Hoedemaeker RF, Kranse R. Prostate cancer detection at low prostate specific antigen. Journal of Urology 2000;163(3):806–812. (slide 25)

Schwartz LM, Woloshin S, Welch HG. Risk communication in clinical practice: putting cancer in context. Journal of the National Cancer Institute Monographs 1999;25:124–133. (slides 35, 36)

Seaward SA, Weinberg V, Lewis P, Leigh B, Phillips TL, Roach M III. Improved freedom from PSA failure with whole pelvic irradiation for high-risk prostate cancer. International Journal of Radiation, Oncology, Biology, Physics 1998;42(5):1055–1062. (slide 30)

Seidenfeld J, Samson DJ, Aronson N, et al. Relative effectiveness and cost-effectiveness of methods of androgen suppression in the treatment of advanced prostate cancer. Evidence Report/Technology Assessment (Summ, No. 4. Rockville, MD: Agency for Health Care Policy and Research; 1999; 4:i–x, 1–246, I1–36, passim. (slide 30)

Sheridan SL, Harris RP, Woolf SH, for the Shared Decisionmaking Workgroup, Third U.S. Preventive Services Task Force. Current methods of the U.S. Preventive Services Task Force: a review of the process. American Journal of Preventive Medicine 2004;26(1):56-66.

Shipley WU, Thames HD, Sandler HM, Hanks GE, Zietman AL, Perez CA, Kuban DA, Hancock SL, Smith CD. Radiation therapy for clinically localized prostate cancer: a multi-institutional pooled analysis. JAMA 1999;281(17):1598–1604. (slide 19)

Shrader-Bogen CL, Kjellberg JL, McPherson CP, Murray, CL. Quality of life and treatment outcomes: prostate carcinoma patients’ perspectives after prostatectomy or radiation therapy. Cancer 1997;79(10):1977–1986. (slide 30)

Siegel T, Maul JW, Spevak M, Alvord WG, Costabile RA. The development of erectile dysfunction in men treated for prostate cancer. Journal of Urology 2001;165(2):430–435. (slide 30)

Stanford JL, Feng Z, Hamilton AS, Gilliland FD, Stephenson RA, Eley JW, Albertsen PC, Harlan LC, Potosky AL. Urinary and sexual function after radical prostatectomy for clinically localized prostate cancer: the Prostate Cancer Outcomes Study. JAMA 2000;283(3):354–360. (slide 30)

Stanford JL, Stephenson RA, Coyle LM, et al. Prostate Cancer Trends 1973–1995, Bethesda, MD: SEER Program, National Cancer Institute; 1999. NIH publication 99–4543. (slides 10, 17, 29)

Steineck G, Helgesen F, Adolfsson J, Dickman PW, Johansson J. Quality of life after radical prostatectomy or watchful waiting. New England Journal of Medicine 2002:347(11):790–796. (slide 30)

Stock RG, Kao J, Stone NN. Penile erectile function after permanent radioactive seed implantation for treatment of prostate cancer. Journal of Urology 2001;165(2):436–439. (slide 30)

Strum SB, McDermed JE, Scholz MC, Johnson H, Tisman G. Anaemia associated with androgen deprivation in patients with prostate cancer receiving combined hormone blockade. British Journal of Urology 1997;79(6):933–941. (slide 30)

Talcott JA, Reiker P, Clark JA, et al. Patient-reported symptoms after primary therapy for early prostate cancer: results of a prospective cohort study. Journal of Clinical Oncology 1998;16:275–283. (slide 30)

Talcott JA, Reiker P, Propert KJ, Clark JA, Wishnow JI, Loughlin KR, Richie JP, Kantoff PW. Patient-reported impotence and incontinence after nerve-sparing radical prostatectomy. Journal of the National Cancer Institute 1997;89(15):1117–1123. (slide 30)

Tarone RE, Chu KC, Brawley OW. Implications of stage-specific survival rates in assessing recent declines in prostate cancer mortality rates. Epidemiology 2000;11(2):167–170. (slide 21)

Taylor KL, Turner RO, Davis JL III, Johnson L, Schwartz MD, Kerner J, Leak C. Improving knowledge of the prostate cancer screening dilemma among African American men: an academic-community partnership in Washington, DC. Public Health Report 2001;116(6):590–598. (slides 35, 36)

Tovar-Guzman V, Hernandez-Giron C, Lopez-Rios O, Lazcano-Ponce EC. Prostate cancer mortality trends in Mexico, 1980–1995. Prostate 1999;39(1):23–27. (slide 21)

US Preventive Services Task Force. Guide to Clinical Preventive Services, 3rd Edition, 2000–2003. Washington, DC: US Dept of Health and Human Services; 2002. (slides 2, 10, 35)

US Preventive Services Task Force. Hormone Replacement Therapy for Primary Prevention of Chronic Conditions: Recommendations and Rationale. Rockville, MD: Agency for Healthcare Research and Quality; 2002. (slide 37)

US Preventive Services Task Force. Screening for Colorectal Cancer: Recommendations and Rationale. Originally in Ann Intern Med. 2002;137:129–131. Rockville, MD: Agency for Healthcare Research and Quality; 2002. (slide 37)

Vainio H, Bianchini F, eds. Weight Control and Physical Activity. Washington, DC: IARC Press; 2002:6. IARC Handbooks of Cancer Prevention. (slide 12)

Volk RJ, Cass AR, Spann SJ. A randomized controlled trial of shared decision making for prostate cancer screening. Archives of Family Medicine 1999;8(4):333–340. (slides 39, 40, 41, 42, 43)

Walsh PC, Marschke P, Ricker D, Burnett AL. Patient-reported urinary continence and sexual function after anatomic radical prostatectomy. Urology 2000;55(1):58–61. (slide 30)

Walsh PC, Partin AW, Epstein JI. Cancer control and quality of life following anatomical radical retropubic prostatectomy: results at 10 years. Journal of Urology 1994;152(5 Pt 2):1831–1836. (slide 19)

Wasson JH, Cushman CC, Bruskewitz RC, Littenburg B, Mulley AG Jr, Wennberg JE. A structured literature review of treatment for localized prostate cancer. Prostate Disease Patient Outcome Research Team. Archives of Family Medicine 1993;2(5):487–493. (slide 30)

Widmark A, Fransson P, Tavelin B. Self-assessment questionnaire for evaluating urinary and intestinal late side effects after pelvic radiotherapy in patients with prostate cancer compared with an age-matched control population. Cancer 1994;74(9):2520–2532. (slide 30)

Wilkins E, Lowery J, Hamill J. The impact of shared decision making in prostate specific antigen (PSA) screening. Medical Decision Making 1999;19:525. (slides 39, 40, 41, 42, 43)

Wilt TJ, Murdoch M, Nelson D, Nugent S, Rubins HB. Educating men about prostate cancer screening. A randomized trial of a mailed pamphlet. Effective Clinical Practice 2001;4(3):112–120. (slides 39, 40, 41, 42, 43)

Wolf AM, Nasser JF, Schorling JB. The impact of informed consent on patient interest in prostate-specific antigen screening. Archives of Internal Medicine 1996;156(12):1333–1336. (slides 39, 40, 41, 42, 43)

Wolf AM, Schorling JB. Preferences of elderly men for prostate-specific antigen screening and the impact of informed consent. Journal of Gerontology Series A: Biological Sciences and Medical Sciences 1998;53(3):M195–M200. (slides 39, 40, 41, 42, 43)

Woolf S. Shared decision-making: the case of letting patients decide which choice is best. Journal of Family Practice 1997;45(3):205–208. (slides 35, 36, 38, 39, 40, 41, 42, 43)

Yao SL, Lu-Yao G. Understanding and appreciating overdiagnosis in the PSA era. Journal of the National Cancer Institute 2002;94(13):958–960. (slides 11, 26, 27, 28, 29)

Zincke H, Bergstralh EJ, Blute MJ, Myers RP, Barrett DM, Lieber MM, Martin SK, Oesterling JE. Radical prostatectomy for clinically localized prostate cancer: long-term results of 1,143 patients from a single institution. Journal of Clinical Oncology 1994;12(11):2254–2263. (slide 19)

Zincke H, Oesterling JE, Blute MJ, Bergstralh EJ, Myers RP, Barrett DM. Long-term (15 years) results after radical prostatectomy for clinically localized (stage T2c or lower) prostate cancer. Journal of Urology 1994;152(5 Pt 2):1850–1857. (slide 19)